Genomenon is a technology company.
Genomenon has raised $27.0M across 3 funding rounds.
Genomenon has raised $27.0M in total across 3 funding rounds.
Genomenon has raised $27.0M in total across 3 funding rounds.
Genomenon's investors include Beringea, General Catalyst, Operator Collective, Vitalize Venture Group.
Genomenon is a genomic intelligence technology company that builds advanced AI-powered platforms to curate and interpret the entire human genome, transforming complex genomic data into actionable insights for clinical and research use. Its flagship product, the Mastermind Genomic Intelligence Platform, serves clinical laboratories, researchers, and precision medicine developers by accelerating variant interpretation and improving diagnostic yield in genetic diseases and cancer. Genomenon addresses the critical challenge of managing the rapidly growing volume and complexity of genomic data, enabling faster, more accurate patient diagnosis and supporting drug development efforts with comprehensive, curated genomic evidence[1][2][7].
Founded in 2014 by Dr. Mark Kiel, a physician-scientist with expertise in genomics, Genomenon emerged from a vision to bridge the gap between genomic research and clinical practice. The company’s early focus was on developing a genomic search engine to unlock buried genomic data in clinical literature. Over the years, Genomenon expanded its capabilities, achieving key milestones such as launching the Mastermind platform in 2017, curating genomic data for pharmaceutical customers starting in 2019, and pioneering the clinical exome curation at the gene level in 2023—two decades ahead of comparable NIH projects. This evolution reflects a decade-long commitment to innovation in genomic medicine, with pivotal moments including strategic acquisitions and expanding expert curation teams to realize the goal of fully curating the human genome at the variant level[4].
Genomenon rides the wave of rapid advances in next-generation sequencing (NGS) technologies, which have exponentially increased genomic data volume and complexity. The timing is critical as whole exome and whole genome sequencing replace older diagnostic methods, creating a pressing need for scalable, accurate interpretation tools. By organizing and curating genomic knowledge into actionable intelligence, Genomenon addresses a major bottleneck in precision medicine—translating raw genomic data into clinical insights. This not only accelerates diagnosis and treatment of genetic diseases and cancer but also supports drug discovery and development, influencing the broader ecosystem of genomic research, diagnostics, and therapeutics[1][2][4].
Genomenon is poised to continue expanding its genomic curation to cover the entire human genome at the variant level, a transformative step that could redefine personalized medicine. Future trends shaping its journey include increasing adoption of genomic sequencing in newborn screening, rare disease diagnosis, and oncology, alongside growing demand for AI-driven data interpretation. As genomic data grows, Genomenon’s influence will likely deepen, enabling faster, more precise diagnostics and accelerating precision drug development. Its ongoing partnerships and technological innovations position it as a critical enabler in the evolving landscape of genomic medicine, with the potential to save more lives through earlier and more accurate genetic insights[4][5].
Genomenon has raised $27.0M across 3 funding rounds. Most recently, it raised $20.0M Series B in March 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2022 | $20.0M Series B | Beringea | |
| Mar 1, 2021 | $5.0M Series A | General Catalyst, Operator Collective, Vitalize Venture Group | |
| Jan 1, 2019 | $2.0M Seed | General Catalyst, Operator Collective, Vitalize Venture Group |